Vaxart Provides Business Update
17 juin 2024 16h05 HE
|
Vaxart, Inc.
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and...
Vaxart Announces $40 Million Underwritten Offering of Common Stock
13 juin 2024 19h07 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering...
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
13 juin 2024 16h15 HE
|
Vaxart, Inc.
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 mai 2024 16h01 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024, the Compensation Committee of the Board of...
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
13 mai 2024 16h01 HE
|
Vaxart, Inc.
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants ...
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13
07 mai 2024 08h00 HE
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
30 avr. 2024 08h00 HE
|
Vaxart, Inc.
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30,...
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
27 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 mars 2024 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors...
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 mars 2024 16h01 HE
|
Vaxart, Inc.
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...